Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

ADMS has been the subject of a number of other research reports. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Friday, May 12th. Mizuho reiterated a “buy” rating and issued a $26.00 price objective on shares of Adamas Pharmaceuticals in a report on Tuesday, June 6th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $45.00 price objective on shares of Adamas Pharmaceuticals in a report on Sunday, May 28th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $28.50.

Shares of Adamas Pharmaceuticals (NASDAQ ADMS) traded down 1.24% during trading on Tuesday, reaching $16.77. The company had a trading volume of 99,562 shares. The firm’s market capitalization is $374.96 million. The company has a 50 day moving average of $16.54 and a 200-day moving average of $16.75. Adamas Pharmaceuticals has a 52-week low of $12.10 and a 52-week high of $19.50.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, meeting analysts’ consensus estimates of ($0.72). Adamas Pharmaceuticals had a negative return on equity of 45.19% and a negative net margin of 10,499.65%. During the same period in the prior year, the firm earned ($0.65) earnings per share. Equities analysts expect that Adamas Pharmaceuticals will post ($3.47) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/11/adamas-pharmaceuticals-inc-adms-upgraded-to-hold-by-zacks-investment-research.html.

In related news, major shareholder Great Point Partners Llc sold 380,000 shares of the company’s stock in a transaction dated Wednesday, June 21st. The stock was sold at an average price of $17.08, for a total value of $6,490,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 731,041 shares of company stock valued at $12,476,149 in the last quarter. 29.00% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in ADMS. Vanguard Group Inc. increased its stake in shares of Adamas Pharmaceuticals by 10.3% in the first quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock valued at $12,537,000 after buying an additional 66,825 shares during the period. State Street Corp boosted its position in shares of Adamas Pharmaceuticals by 6.3% in the fourth quarter. State Street Corp now owns 257,685 shares of the specialty pharmaceutical company’s stock valued at $4,356,000 after buying an additional 15,216 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Adamas Pharmaceuticals by 29.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 126,494 shares of the specialty pharmaceutical company’s stock valued at $2,138,000 after buying an additional 28,994 shares during the period. Geode Capital Management LLC boosted its position in shares of Adamas Pharmaceuticals by 4.9% in the first quarter. Geode Capital Management LLC now owns 125,793 shares of the specialty pharmaceutical company’s stock valued at $2,201,000 after buying an additional 5,920 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its position in shares of Adamas Pharmaceuticals by 153.3% in the first quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock valued at $1,956,000 after buying an additional 67,654 shares during the period. Institutional investors own 70.47% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.